John Iafrate, M.D., Ph.D., Jeffrey A. Engelman, M.D., Ph.D., and Alice T. Shaw, M.D., Ph.D. The identification of activating mutations within the kinase domain of the epidermal development factor receptor 2,3 has led to the widespread use of kinase inhibitors in this genetically described subset of lung cancers.4 Recently, chromosomal translocations that create fusion proteins involving the tyrosine kinase domains of ALK5 or ROS16 have been the main topic of intense investigation in lung adenocarcinoma due to the option of clinically active inhibitors of these kinases. Although kinase inhibitors could be effective highly, most cancers acquire level of resistance to these targeted therapies invariably, an effect that represents a significant limitation with their long-term clinical benefit.Related StoriesNew Cleveland Clinic study shows bariatric surgery is safe choice for managing type 2 diabetes in overweight or mildly obese patientsStudy explores diabetes screening for sufferers with serious mental illnessBetalin launches fresh EMP technology that could transform diabetes treatmentAfrezza is not a substitute for long-performing insulin. Afrezza can be used in combination with long-performing insulin in individuals with type 1 diabetes, and it is not really recommended for the treatment of diabetic ketoacidosis, or in sufferers who smoke. Afrezza includes a Boxed Warning advising that acute bronchospasm has been seen in sufferers with asthma and chronic obstructive pulmonary disease .